Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by<i>Enterobacter</i>,<i>Citrobacter</i>or<i>Serratia</i>species: a systematic review with meta-analysisPatrick N. A. Harris, David L. Paterson, Stuart Paynter et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 86
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12